Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights


Werte in diesem Artikel
Aktien

1.18 EUR 0.07 EUR 6.35 %

Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET

CAMBRIDGE, Mass., Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, prior to the open of financial markets.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

Akebia will host a conference call on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please dial (800) 715-9871 (USA & Canada - Toll-Free) and enter Conference ID: 4155557.

A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-second-quarter-2024-financial-results-and-discuss-recent-business-highlights-302213120.html

SOURCE Akebia Therapeutics, Inc.

Aktuelle Akebia Therapeutics Aktie News

Werbung

Akebia Therapeutics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Akebia Therapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
06.08.19 Akebia Therapeutics Buy H.C. Wainwright & Co.
11.07.19 Akebia Therapeutics Buy H.C. Wainwright & Co.
10.08.18 Akebia Therapeutics Buy Needham & Company, LLC
06.06.18 Akebia Therapeutics Buy H.C. Wainwright & Co.
07.12.17 Akebia Therapeutics Buy BTIG Research